Michel Dahan - 01 Mar 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Operating Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Issuer symbol
AKBA
Transactions as of
01 Mar 2023
Net transactions value
-$17,912
Form type
4
Filing time
03 Mar 2023, 07:01:05 UTC
Previous filing
01 Mar 2023
Next filing
16 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale $7,071 -8,058 -2.8% $0.8775 281,869 01 Mar 2023 Direct F1
transaction AKBA Common Stock Sale $9,193 -10,476 -3.7% $0.8775 271,393 01 Mar 2023 Direct F2
transaction AKBA Common Stock Sale $1,648 -1,878 -0.69% $0.8775 269,515 01 Mar 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
F3 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.